Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

Exclusion Criteria

• •Patient treated with topical scalp treatment for scalp psoriasis within two weeks prior to the inclusion in the study (corticoids, retinoids, vitamin D derivatives),
• •Patient treated with systemic treatment for psoriasis (biologics, methotrexate, cyclosporine, retinoids) within one month prior to the inclusion in the study
• •Patient taking systemic niacin or multivitamins within past two weeks
• •Patient who start or modify a treatment with beta-blockers within one month prior to the inclusion in the study
• •Patient with PEG (Poly Ethylene Glycol) allergy
• •Pregnant or breast feeding female or female who do not use contraception,
• •Patient with an history of hypersensitivity to Dovonex/Daivonex
• •Patient who has participated in a clinical trial within three month prior inclusion,
• •Patients on Carbamazepine and Primidione (the clearance of Primidione and Carbamazepine may be reduced with the concomitant use of Nicotinamide)
• •Patient who is under guardianship, or unable to understand the information (for linguistic or mental reason), or unwilling to give her/his informed consent to participate in the study